Small-Molecule-Anti-infective-Drug-Market-

Small Molecule Anti-infective Drug Market
Provides An In-Depth Insight Of Sales And Trends
Forecast To 2026
Small Molecule Anti-infective Drug Market, by Product Type (Antibiotics (B
Lactam, Quinolones, Macrolides, Tetracyclines, Aminoglycosides,
Sulphonamides, and Others), Antifungal ( Azoles, Echinocandins, Polyenes, and
Others), Antivirals (Nucleoside Reverse Transcriptase Inhibitors, Non-nucleoside
Reverse Transcriptase Inhibitors, and Others), and Others (Anthelminthic and
Antiprotozoal), by Indication (Pneumonia, MRSA Infections, MSSA Infections,
Sinusitis, Tuberculosis, Dermatophytosis, Aspergillosis, Candidiasis, Hepatitis,
HIV Infection, Respiratory Tract Infection, Urinary Tract Infection, and Others),
by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), and by Region (North America, Europe, Asia Pacific, Latin
America, Middle East, and Africa) - Global Industry Insights, Trends, Outlook,
and Opportunity Analysis, 2019 – 2026
Small molecule anti-infective drugs are used for the treatment of various infectious diseases such as
Methicillin-resistant Staphylococcus aureus (MRSA) infections, Methicillin-Susceptible
Staphylococcus aureus (MSSA) infections, sinusitis, cellulitis, pneumonia, tuberculosis, aspergilosis,
and hepatitis. Anti-infective drugs have the capability to eliminate and suppress infections that are
caused by various bacteria and viruses. Click To Read More On Small Molecule Anti-infective Drug
Market.
Small Molecule Anti-infective Drug Market Drivers
Increasing approval of new drugs is expected to drive growth of the global small molecule antiinfective drug market. For instance, in April 2019, the U.S. Food and Drug Administration (FDA)
announced the approval of Dovato (dolutegravir and lamivudine), which is used for the treatment of
HIV-1 infection in adults. It is manufactured by ViiV Healthcare.
Furthermore, in August 2018, Tetraphase Pharmaceuticals received the U.S. Food and Drug
Administration approval for its new drug, Xerava containing Eravacycline, which is used for the
treatment of complicated intra-abdominal infections (CIAI).
Small Molecule Anti-infective Drug Market Restraints
Increasing severe side effect of drugs is the major restraining factor of anti-infective drug market, it is
expected to the hamper the small molecule anti-infective drug market growth. For instance, NBC news
report in December 2018, U.S Food and drug administration sends warning letters to Fluroquinonolone
antibiotics because U.S FDA found that Fluroquinolones antibiotic can increase the occurrence of
serious events of rupture in the main artery of the body. These ruptures called as the aortic dissections.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/2655
Key players operating in the global small molecule anti-infective market include, Merck & Co., Inc.,
AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, Bayer AG, Pfizer,
Inc., Sanofi, GlaxoSmithKline plc. (GSK),and Allergan plc.
Small Molecule Anti-infective Drug Market Taxonomy
By Product Type
*Antibiotics : B Lactam, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulphonamide,
Others, Antifungal Drugs, Azoles, Echinocandins, Polyenes, Others.
*Antiviral Drugs : Nucleoside Reverse Transcriptase Inhibitors, Non-nucleoside Reverse Transcriptase
Inhibitor Others
*Others : Anthelminthic Antiprotozoal
By Indication : Pneumonia, MRSA Infections, MSSA Infections, Sinusitis, Tuberculosis,
Dermatophytosis, Aspergillosis, Candidiasis, Hepatitis, HIV Infection, Respiratory Tract Infection,
Urinary Tract Infection, Others.
Small Molecule Anti-infective Drug Market Regional Analysis
On the basis of region, the global small molecule anti-infective drug market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the small molecule anti-infective drugs market,
owing to new product launches of small molecule anti-infective drugs. For instance, in November
2018, Xellia Pharmaceuticals launched its new product, Vancomycine Hydrochloride for injection, in
the U.S market.
Furthermore, Asia Pacific is also projected to witness significant growth in the global small molecule
anti-infective drugs market, owing to increasing collaboration activities among key players. For
instance, in April 2018, Entasis Therapeutics Holdings Inc. collaborated with the Zai Lab Limited. This
collaboration facilitated phase III clinical trial for a fixed-dose combination of ETX2514 and
sulbactam. This combination is intended for the treatment of multidrug-resistant infections caused by
Acinetobacter baumannii bacteria. The study started in April 2019 and is expected to complete in July
2020.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Download Report